Research programme: Anti-CD19 CAR therapies - Orna Therapeutics
Latest Information Update: 11 Jul 2024
At a glance
- Originator Orna Therapeutics
- Class Cell therapies; Gene therapies; RNA
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Autoimmune disorders
Most Recent Events
- 26 Jun 2024 Early research in Autoimmune disorders in USA (Parenteral) prior to June 2024 (Orna Therapeutics pipeline, June 2024)
- 26 Jun 2024 Orna Therapeutics plans IND-enabling studies in Autoimmune disorders in 2026 (Orna Therapeutics pipeline, June 2024)